More evidence of ubrogepant effectiveness in migraine pain

Takeaway

• Patients who received ubrogepant for treatment of migraine had greater pain relief and decrease in the most bothersome migraine symptoms at 2 hours than those who received a placebo.

Why this matters

• This study confirms earlier research that found ubrogepant to be effective at treating acute migraine.  

Study design

• This randomized, double-blind, parallel-group trial evaluated the efficacy, safety, and side-effect profile of ubrogepant in patients with a history of migraine (≥1 year).
• Treatment received: placebo (n=456), 50-mg ubrogepant (n=423), or 100-mg ubrogepant (n=448).
• Funding: Allergan.

Key results

• The number of participants with freedom from migraine pain at 2 hours:
  • placebo group, 11.8%;
  • 50-mg ubrogepant group, 19.2% (vs placebo; OR, 1.83; P_adjusted=.002); and
  • 100-mg ubrogepant group, 21.2% (vs placebo; OR, 2.04; P_adjusted<.001).
• Absence of the most bothersome symptom at 2 hours:
  • placebo group, 27.8%;
  • 50-mg ubrogepant group, 38.6% (vs placebo; OR, 1.70; P_adjusted=.002); and
  • 100-mg ubrogepant group, 37.7% (vs placebo; OR, 1.63; P_adjusted=.002). 
• Any adverse events reported:
  • placebo group, 12.8%;
  • 50-mg ubrogepant group, 9.4%; and
  • 100-mg ubrogepant group, 16.3%.
• Most common adverse events reported within 48 hours were nausea, somnolence, and dry mouth.

Limitations

• Limited generalizability.

Coauthored by Chitra Ravi, MPharm